ADAM KAPLIN, M.D.
Psychiatric at Wolfe St, Baltimore, MD
License number
Maryland D54054
Category
Psychiatric
Type
Psychiatry
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-5104
Personal information
See more information about ADAM KAPLIN at radaris.comName
Address
Phone
639 Anneslie Rd, Baltimore, MD 21212
639 Anneslie Rd, Baltimore, MD 21212
1000 Fell St, Baltimore, MD 21231
1000 Fell St, Baltimore, MD 21231
Professional information
Chief Psychiatric Consultant Johns Hopkins Multiple Sclerosis &Amp; Transverse Myelitis Centers Of Excelence
Position:
Faculty at Johns Hopkins University, Principal Psychiatric Consultant to the JH MS Center at Johns Hopkins School of Medicine, Departments of Psychiatry & Neurology at Johns Hopkins Hospital, CEO/ President at Altammune, Chief Scientific and Medical Advisor at Montel Williams MS Foundation
Location:
Baltimore, Maryland Area
Industry:
Research
Work:
Johns Hopkins University
since 1990
-
Faculty
Johns Hopkins School of Medicine
since Jan 2001
-
Principal Psychiatric Consultant to the JH MS Center
Johns Hopkins Hospital
since 2002
-
Departments of Psychiatry & Neurology
Altammune
since 2010
-
CEO/ President
Montel Williams MS Foundation
since 2008
-
Chief Scientific and Medical Advisor
HealthCentral
2009 - 2011
-
Consultant
Multiple sclerosis Association of America
2000 - 2010
-
Consultant
NCUSCR
2005 - 2009
-
YLF
Nerveda
2007 - 2008
-
Prior Consultant
Education:
The Johns Hopkins University School of Medicine 1990 - 1996
MD, PhD, Neuropsychiatry Yale University 1985 - 1988
BS, Biology
MD, PhD, Neuropsychiatry Yale University 1985 - 1988
BS, Biology
Skills:
Medical Education, Psychiatry, Neurology, Biotechnology, Clinical Research, Leadership, Start-ups, Medicine, Lifesciences, Statistics, Policy Analysis, Public Health, Project Management, Non-profits, Editing, Teaching, Therapists, Neuroscience, Molecular Biology, Science
Interests:
Multiple Sclerosis, Biological Basis of Depression and Dementia, Cytokines and the Immune-Brain-Mind Interface
Adam Ian Kaplin, Baltimore MD
Specialties:
Family Medicine, Psychiatry
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
Education:
Johns Hopkins University (1996)
Dr. Adam I Kaplin, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
600 N Wolfe St, Baltimore 21287
Johns Hopkins Mdcl Ctr Psych
600 N Wolfe St SUITE 121, Baltimore 21287
(410) 955-2343 (Phone)
Johns Hopkins Mdcl Ctr Psych
600 N Wolfe St SUITE 121, Baltimore 21287
(410) 955-2343 (Phone)
Certifications:
Psychiatry, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
600 N Wolfe St, Baltimore 21287
Johns Hopkins Mdcl Ctr Psych
600 N Wolfe St SUITE 121, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Johns Hopkins Mdcl Ctr Psych
600 N Wolfe St SUITE 121, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Johns Hopkins Univ Sch Of Med
Graduated: 1993
Johns Hopkins Univ Sch Of Med
Graduated: 1993
System And Method For Patient Self-Assessment Or Treatment Compliance
US Patent:
2011023, Sep 22, 2011
Filed:
Dec 17, 2009
Appl. No.:
13/130739
Inventors:
Adam Ian Kaplin - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
G06Q 50/00, G06F 15/16, G06Q 10/00
US Classification:
705 3, 709206
Abstract:
A system and method for transmission of alphanumeric messaging between mobile subscribers and an external system to send messages directly to the mobile subscriber's existing mobile phone to query them, for example, on the psychometric scale of interest. The resulting daily assessments may then be stored in a database that may be accessed via the interne to aid both the patient and a care provider in tracking the state and progress of the illness or symptoms which are being treated. It may allow the database to be queried to display trends over varying time intervals at any time in the past. The system and method may also provide for automatically notifying care providers if the patient is acutely having severe symptoms for a redefined duration and severity, and may facilitate a way to increase patient compliance with monitoring.
Use Of High-Dose Oxazaphosphorine Drugs In Combination With Monoclonal Antibodies For Treating Immune Disorders
US Patent:
2012012, May 24, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/240465
Inventors:
Robert A. Brodsky - Brooklandville MD, US
Richard J. Jones - Baltimore MD, US
Susan Bonitz - Flemington NJ, US
Carlos Santos - Tampa FL, US
Adam Kaplin - Baltimore MD, US
Richard J. Jones - Baltimore MD, US
Susan Bonitz - Flemington NJ, US
Carlos Santos - Tampa FL, US
Adam Kaplin - Baltimore MD, US
Assignee:
Accentia Biopharmaceuticals, inc. - Tampa FL
The Johns Hopkins University - Baltimore MD
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, A61P 37/00
US Classification:
4241531
Abstract:
The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.
Method Of Identifying Patients Suitable For High-Dose Cyclophosphamide Treatment
US Patent:
2012012, May 24, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/240443
Inventors:
Robert A. Brodsky - Brooklandville MD, US
Richard J. Jones - Baltimore MD, US
Susan Bonitz - Flemington NJ, US
Adam Kaplin - Baltimore MD, US
Carlos Santos - Tampa FL, US
Richard J. Jones - Baltimore MD, US
Susan Bonitz - Flemington NJ, US
Adam Kaplin - Baltimore MD, US
Carlos Santos - Tampa FL, US
Assignee:
Accentia Biopharmaceuticals, Inc. - Tampa FL
The Johns Hopkins University - Baltimore MD
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/32
US Classification:
435 26
Abstract:
The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.
Methods And Compositions For Treating Or Preventing Autoimmune Diseases Using Immunomodulatory Agents
US Patent:
2012023, Sep 20, 2012
Filed:
Jul 23, 2010
Appl. No.:
13/386730
Inventors:
Adam Ian Kaplin - Baltimore MD, US
Mark T. Worthington - Prescott AZ, US
Mark T. Worthington - Prescott AZ, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 38/02, A61K 38/07, A61K 38/10, A61K 38/17, A61K 38/08, A61K 38/19, A61P 37/06, A61P 37/02, A61P 1/00, A61P 29/00, A61P 19/02, A61P 3/10, A61P 3/00, A61P 5/14, A61P 1/16, A61P 5/38, A61K 39/395
US Classification:
424 851, 4242781, 4241731, 4241331, 4241421
Abstract:
The present invention provides compositions and methods for treating and/or preventing an autoimmune disease comprising administering to a subject in need thereof an effective amount of cyclophosphamide and/or a cyclophosphamide derivative in combination with an additional immunomodulatory agent.
Treatment Of Cognitive Impairment In A Subject With A Neurological Autoimmune Disease
US Patent:
2013034, Dec 26, 2013
Filed:
Dec 14, 2011
Appl. No.:
13/994514
Inventors:
Adam Kaplin - Baltimore MD, US
Barbara S. Slusher - Kingsville MD, US
Kristen A. Rahn - Baltimore MD, US
Barbara S. Slusher - Kingsville MD, US
Kristen A. Rahn - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/662, A61K 49/06
US Classification:
424 93, 514121
Abstract:
Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment.
Methods Of Treating Neurological Autoimmune Disorders With Cyclophosphamide
US Patent:
2011012, May 26, 2011
Filed:
Oct 1, 2008
Appl. No.:
12/681237
Inventors:
Adam Ian Kaplin - Baltimore MD, US
Douglas Kerr - Ruxton MD, US
Peter Arthur Calabresi - Lutherville MD, US
Sithy Rameeza Allie - Lebanon NH, US
Douglas Kerr - Ruxton MD, US
Peter Arthur Calabresi - Lutherville MD, US
Sithy Rameeza Allie - Lebanon NH, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 38/19, C12Q 1/32, C07F 9/6584, A61K 31/675, A61P 25/00, A61P 25/18
US Classification:
424 851, 435 26, 564 13, 514110
Abstract:
Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system.
Methods And Compositions Of Treating And Preventing Autoimmune Diseases
US Patent:
2011021, Sep 1, 2011
Filed:
Jul 24, 2009
Appl. No.:
13/055880
Inventors:
Adam Kaplin - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 38/19, A61K 39/395, A61P 19/02, A61P 37/06, A61P 5/14, A61P 1/00, A61P 3/10
US Classification:
424 851, 4241731
Abstract:
Provided are methods and compositions for treating and/or preventing an autoimmune diseases, including inflammatory bowel disease, rheumatoid arthritis, diabetes mellitus, celiac disease, autoimmune thyroid disease, autoimmune liver disease, Addison's Disease, Sjögren's Syndrome, transplant rejection, graft vs. host disease, or host vs. graft disease.